JP2002532542A - 性的不全の処置における吸入用ｃＧＭＰＰＤＥ５阻害剤 - Google Patents

性的不全の処置における吸入用ｃＧＭＰＰＤＥ５阻害剤

Info

Publication number
JP2002532542A
JP2002532542A JP2000589172A JP2000589172A JP2002532542A JP 2002532542 A JP2002532542 A JP 2002532542A JP 2000589172 A JP2000589172 A JP 2000589172A JP 2000589172 A JP2000589172 A JP 2000589172A JP 2002532542 A JP2002532542 A JP 2002532542A
Authority
JP
Japan
Prior art keywords
pyrimidin
inhibitor
pyrazolo
methyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000589172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532542A5 (es
Inventor
レト・ネーフ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2002532542A publication Critical patent/JP2002532542A/ja
Publication of JP2002532542A5 publication Critical patent/JP2002532542A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000589172A 1998-12-22 1999-12-21 性的不全の処置における吸入用ｃＧＭＰＰＤＥ５阻害剤 Pending JP2002532542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9828340.1 1998-12-22
GBGB9828340.1A GB9828340D0 (en) 1998-12-22 1998-12-22 Organic compounds
PCT/EP1999/010250 WO2000037061A2 (en) 1998-12-22 1999-12-21 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION

Publications (2)

Publication Number Publication Date
JP2002532542A true JP2002532542A (ja) 2002-10-02
JP2002532542A5 JP2002532542A5 (es) 2007-01-25

Family

ID=10844812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589172A Pending JP2002532542A (ja) 1998-12-22 1999-12-21 性的不全の処置における吸入用ｃＧＭＰＰＤＥ５阻害剤

Country Status (11)

Country Link
US (3) US20010055570A1 (es)
EP (1) EP1140044B1 (es)
JP (1) JP2002532542A (es)
AT (1) ATE320247T1 (es)
AU (1) AU3041900A (es)
CA (1) CA2355368A1 (es)
DE (1) DE69930416T2 (es)
ES (1) ES2260952T3 (es)
GB (1) GB9828340D0 (es)
PT (1) PT1140044E (es)
WO (1) WO2000037061A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516044A (ja) * 2011-05-25 2014-07-07 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン 肺に投与するための活性成分を含有する生体適合性ナノポリマー粒子

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6919337B2 (en) 2000-04-07 2005-07-19 Novartis, Ag 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US7019136B2 (en) 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
KR20080015594A (ko) * 2006-08-16 2008-02-20 주식회사종근당 포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
KR101129868B1 (ko) 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
US20110225023A1 (en) * 2010-03-09 2011-09-15 Target Brands, Inc. Prioritized Product Distribution

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JPH06192235A (ja) * 1992-07-15 1994-07-12 Ono Pharmaceut Co Ltd ４−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品
JPH09512834A (ja) * 1994-11-26 1997-12-22 ファイザー・インコーポレーテッド 勃起機能不全の治療のためのｃＧＭＰ−ＰＤＥ阻害薬
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
JP2000034232A (ja) * 1998-06-22 2000-02-02 Pfizer Inc 性障害を治療するための鼻内用製剤
JP2002521424A (ja) * 1998-07-24 2002-07-16 ヤゴ・リサーチ・アクチェンゲゼルシャフト 医薬用エーロゾル製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4420708A1 (de) * 1994-06-14 1995-12-21 Euro Celtique Sa Entzündungshemmende Zusammensetzung zur Inhalation
HUP9801394A3 (en) * 1995-03-10 2000-07-28 Sanofi Pharmaceuticals Inc New 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
JPH11505539A (ja) * 1995-05-18 1999-05-21 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルジヒドロベンゾフラン
AU698028B2 (en) * 1995-05-18 1998-10-22 Altana Pharma Ag Phenyldihydrobenzofurans
DE19541264A1 (de) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
CZ289340B6 (cs) * 1996-01-31 2002-01-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenanthridinové deriváty a farmaceutický prostředek s jejich obsahem
KR20000010919A (ko) * 1996-05-31 2000-02-25 모치다 에이 Cgmp­pde 저해작용이 있는 피리도카르바졸 유도체
PT937075E (pt) * 1996-11-11 2004-05-31 Altana Pharma Ag Novas imidazo- e oxazolo-piridinas como inibidores da fosfodiesterese
US6043263A (en) * 1996-11-12 2000-03-28 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE69916627T2 (de) * 1998-09-04 2005-07-28 Ortho-Mcneil Pharmaceutical, Inc. 5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5541187A (en) * 1992-03-30 1996-07-30 Sterling Winthrop Inc. 6-heterocycyclyl pyrazolo[3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JPH06192235A (ja) * 1992-07-15 1994-07-12 Ono Pharmaceut Co Ltd ４−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品
JPH09512834A (ja) * 1994-11-26 1997-12-22 ファイザー・インコーポレーテッド 勃起機能不全の治療のためのｃＧＭＰ−ＰＤＥ阻害薬
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
JP2000034232A (ja) * 1998-06-22 2000-02-02 Pfizer Inc 性障害を治療するための鼻内用製剤
JP2002521424A (ja) * 1998-07-24 2002-07-16 ヤゴ・リサーチ・アクチェンゲゼルシャフト 医薬用エーロゾル製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN7010000020, ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ, 1996, １１８（６）, Ｐ．１３７７−１３８４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516044A (ja) * 2011-05-25 2014-07-07 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン 肺に投与するための活性成分を含有する生体適合性ナノポリマー粒子

Also Published As

Publication number Publication date
WO2000037061A3 (en) 2000-10-26
US20010055570A1 (en) 2001-12-27
DE69930416D1 (de) 2006-05-11
ATE320247T1 (de) 2006-04-15
CA2355368A1 (en) 2000-06-29
EP1140044A2 (en) 2001-10-10
AU3041900A (en) 2000-07-12
GB9828340D0 (en) 1999-02-17
US20070197560A1 (en) 2007-08-23
WO2000037061A2 (en) 2000-06-29
DE69930416T2 (de) 2006-11-02
EP1140044B1 (en) 2006-03-15
US20040214831A1 (en) 2004-10-28
ES2260952T3 (es) 2006-11-01
PT1140044E (pt) 2006-07-31

Similar Documents

Publication Publication Date Title
US20070197560A1 (en) cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction
JP5579368B2 (ja) 慢性呼吸器疾患を治療するためのメチルキサンチン化合物とステロイドの組み合わせ
US6994842B2 (en) Aerogel powder therapeutic agents
JP2023036678A (ja) 肺高血圧症および他の肺障害の処置のための方法および組成物
EP2983645B1 (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
JP2008546786A (ja) Ｐｄｅ５インヒビターの迅速吸収性経口処方物
JP2002506017A (ja) ニコチン吸入器
AU2003273273C1 (en) Trospium containing compositions
AU6178899A (en) Method of treating nitrate-induced tolerance
JP2014516044A (ja) 肺に投与するための活性成分を含有する生体適合性ナノポリマー粒子
MXPA04002354A (es) Composiciones para inhalacion que comprenden 5,6-dihidro-9h-pirazolo (3,4-c)-1,2,4,triazolo-(4,3-alfa)piridinas triciclicas.
JP2002532542A5 (es)
JP2013502579A (ja) リボフラビンベースのエアロゾル及び臨床試験におけるプラセボとしての使用
US20060188451A1 (en) Aerogel based pharmaceutical formulations
CN107362140A (zh) 喷雾剂以及喷雾组件
WO2023212063A1 (en) Method and composition for treating lung diseases
AU2002232689A1 (en) Aerogel powder comprising therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706